Elaine A. Ostrander, Ph.D., a researcher with the National Human Genome Research Institute, contributed to a new study that has implicated 63 additional genetic variants in prostate cancer risk. Dr. Ostrander and her colleagues based their findings, published in Nature Genetics, on DNA samples from more than 140,000 men.
In the June issue of The Genomics Landscape, NHGRI Director Dr. Eric Green highlights the success of The Cancer Genome Atlas, as the program draws to an end. Other topics include the launch of the All of Us Research Program, the retirement of National Institute on Deafness and Other Communication Disorders Director Dr. James Battey to NHGRI Scientific Director Dr. Dan Kastner's selection as a finalist for the 2018 Samuel J. Heyman Service to America Medals.
After more than 10 years, The Cancer Genome Atlas (TCGA) has come to a close. A multi-institution collaboration initiated and supported by NHGRI and the National Cancer Institute (NCI), TCGA has been hugely successful in its mission to catalog the genomic changes underlying multiple cancer types. This video celebrates TCGA's accomplishments with reflections from some of its contributors, including NIH Director Francis S. Collins, M.D. Ph.D., and NHGRI's Division of Genome Sciences Director Carolyn Hutter, Ph.D.
A year ago, 14-year-old Rohith Lokesh spent most of his days barely walking and in a wheelchair. After cutting-edge treatment at the NIH Clinical Center this patient is winning dance contests back in his hometown. This patient's story highlights what the NIH Clinical Center can do that's hard to do somewhere else. From using mechanistic studies and genome sequencing to inform your patient care - that's unique to NIH.
NIH researchers addressed the ethics of using genealogy data to solve crimes in a timely commentary relevant to the recent arrest of the suspected Golden State Killer. In the May 29 issue of the Annals of Internal Medicine, Ben Berkman, J.D., and his colleague highlight the need: to alert users that their data may be used in criminal investigations (informed consent), for safeguards around potential uses of genomic data (privacy) and to limit criminal genealogy to crimes where other investigative methods have failed (justice).